SEC Form 4 · accession 0001437749-17-003885
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeff R. Schroeder
Officer — Chief Commercial Officer
Period of report
Feb 24, 2017
Accepted (ET)
Mar 6, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 24, 2017 | A | 8,737 | $0.00 | A | 101,972 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $13.50 | Feb 24, 2017 | A | 39,683 | A | — | Feb 24, 2027 | Ordinary Shares | 39,683 | 39,683 | D |
Explanation of responses
- F1Option granted under Issuer's 2013 Share Incentive Plan.
- F2Options will become exercisable ratably on the anniversary of the vesting start date from January 1, 2018 through January 1, 2021.